ストックスクリーナーアプリを入手
63.16
0.98%
0.61
前日終値:
$62.55
開ける：
$63.38
24時間の取引高:
402.14K
Relative Volume:
0.67
時価総額：
$2.72B
収益：
$535.08M
当期純損益:
$-48.27M
株価収益率:
-55.72
EPS:
-1.1335
ネットキャッシュフロー:
$-31.54M
1週間 パフォーマンス:
+0.88%
1か月 パフォーマンス:
+0.54%
6か月 パフォーマンス:
-18.48%
1年 パフォーマンス:
+53.79%
1日の値動き範囲:
$62.37
$64.24
1週間の範囲:
$60.08
$64.24
52週間の値動き範囲:
$38.51
$85.25
Tarsus Pharmaceuticals Inc Stock (TARS) Company Profile
名前
Tarsus Pharmaceuticals Inc
セクター
電話
(949) 409-9820
住所
15440 LAGUNA CANYON ROAD, IRVINE
Compare TARS vs VRTX, REGN, ARGX, ALNY, RVMD
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
TARS
Tarsus Pharmaceuticals Inc
|
63.16 | 2.72B | 535.08M | -48.27M | -31.54M | -1.1335 |
VRTX
Vertex Pharmaceuticals Inc
|
451.63 | 114.63B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
609.94 | 63.95B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
877.72 | 54.58B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
278.09 | 37.13B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
162.99 | 34.65B | 742.00K | -1.37B | -1.07B | -7.0731 |
Tarsus Pharmaceuticals Inc Stock (TARS) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-04-24 | 再開されました | Oppenheimer | Outperform |
| 2025-12-09 | 開始されました | Barclays | Overweight |
| 2025-11-20 | 開始されました | Mizuho | Outperform |
| 2025-06-02 | 再開されました | Oppenheimer | Outperform |
| 2025-05-27 | 再開されました | H.C. Wainwright | Buy |
| 2023-11-20 | 開始されました | Goldman | Neutral |
| 2023-07-18 | 開始されました | William Blair | Outperform |
| 2023-05-18 | 開始されました | Guggenheim | Buy |
| 2022-08-01 | 開始されました | Barclays | Overweight |
| 2021-12-21 | 開始されました | H.C. Wainwright | Buy |
| 2021-11-23 | 開始されました | Oppenheimer | Outperform |
| 2020-11-10 | 開始されました | BofA Securities | Buy |
| 2020-11-10 | 開始されました | Jefferies | Buy |
| 2020-11-10 | 開始されました | Ladenburg Thalmann | Buy |
| 2020-11-10 | 開始されました | Raymond James | Strong Buy |
すべてを表示
Tarsus Pharmaceuticals Inc (TARS) 最新ニュース
Tarsus: Not Cheap, But Xdemvy Makes The Valuation Work - Seeking Alpha
Tarsus Pharmaceuticals director sells $183,384 in company stock By Investing.com - Investing.com Canada
Tarsus Pharmaceuticals director sells $183,384 in company stock - Investing.com UK
Tarsus Pharmaceuticals CFO sells $877k in company shares By Investing.com - Investing.com Australia
Tarsus Pharmaceuticals CFO sells $877k in company shares - Investing.com UK
Tarsus Pharmaceuticals director sells $776,495 in company stock By Investing.com - Investing.com Australia
Tarsus Pharmaceuticals director sells $776,495 in company stock - Investing.com
Responsive Playbooks and the TARS Inflection - Stock Traders Daily
Tarsus Pharmaceuticals Inc (TARS) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Tarsus Pharmaceuticals Inc (TARS) Institutional Confidence - TradingKey
Tarsus Pharmaceuticals Inc (TARS) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Tarsus CFO Farrow sells $877k in shares - Investing.com UK
Insider Sell Alert: Katherine Goodrich Sells Shares of Tarsus Ph - GuruFocus
Tarsus director Katherine Goodrich sells $183k in stock By Investing.com - Investing.com South Africa
Tarsus Pharmaceuticals Inc (TARS) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Tarsus Pharmaceuticals Inc (TARS) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Tarsus director Katherine Goodrich sells $183k in stock - Investing.com UK
Tarsus Pharmaceuticals Inc (TARS) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
[Form 4] Tarsus Pharmaceuticals, Inc. Insider Trading Activity - Stock Titan
Tarsus (TARS) director Goodrich sells 2,954 shares in pre-planned trade - Stock Titan
Tarsus (TARS) director William Link sells 12,500 shares in planned 10b5-1 trades - Stock Titan
Tarsus Pharmaceuticals Inc (TARS) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Tarsus Pharmaceuticals Inc (TARS) Valuation: PE, PB & Fair Value Analysis - TradingKey
Tarsus Pharmaceuticals Inc (TARS) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
[144] Tarsus Pharmaceuticals, Inc. SEC Filing - Stock Titan
Tarsus (TARS) director Scott Morrison settles 2,954 RSUs into stock - Stock Titan
Tarsus (TARS) director William Link receives 2,954 shares from RSU vesting - Stock Titan
Director at Tarsus (NASDAQ: TARS) settles 2,954 RSU-based shares - Stock Titan
Tarsus Pharmaceuticals (TARS) director receives 2,954 shares from RSU vesting - Stock Titan
Director Wendy Yarno gains 2,954 Tarsus (TARS) shares from RSU grant - Stock Titan
RSU vesting adds 2,954 Tarsus (TARS) shares to director’s holdings - Stock Titan
Tarsus Pharmaceuticals (NASDAQ: TARS) insider files to sell 12,500 shares - Stock Titan
Tarsus Pharmaceuticals, Inc. Q1 2026 earnings preview - MSN
Is Conference-Spotlighted XDEMVY Adoption Quietly Reshaping the Long-Term Narrative for Tarsus (TARS)? - Sahm
Assessing Tarsus Pharmaceuticals (TARS) Valuation After Recent Share Price Weakness And Strong Longer Term Returns - Sahm
A Look At Tarsus Pharmaceuticals (TARS) Valuation After Recent Share Price Strength And Perceived Discount - Yahoo Finance
Clearbridge Investments LLC Cuts Stake in Tarsus Pharmaceuticals, Inc. $TARS - MarketBeat
Understanding the Setup: (TARS) and Scalable Risk - Stock Traders Daily
Tarsus Pharmaceuticals (NASDAQ:TARS) Upgraded to Buy at Wall Street Zen - MarketBeat
Analysts Are Bullish on Top Healthcare Stocks: Autolus Therapeutics (AUTL), Wuxi Biologics (Cayman) (WXIBF) - The Globe and Mail
TARS Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
William Blair Maintains Tarsus Pharmaceuticals(TARS.US) With Buy Rating - Moomoo
Evaluating Tarsus Pharmaceuticals (TARS) Valuation After Recent Share Price Weakness - Sahm
Tarsus Pharmaceuticals (TARS) Holds Steady Near $59 as Consolidation ContinuesJurik MA - newsline.com
Tarsus Pharmaceuticals (TARS) Holds Steady Near Support as Market Watches Key LevelsPre-Earnings Momentum - newsline.com
Tarsus to Participate in Upcoming Investor Conferences - GlobeNewswire
Two June investor conferences put Tarsus executives on stage - Stock Titan
Tarsus Pharmaceuticals (TARS) Gets a Buy from H.C. Wainwright - The Globe and Mail
The Technical Signals Behind (TARS) That Institutions Follow - Stock Traders Daily
Tarsus Pharmaceuticals (TARS) Shows Resilience Near Support After Moderate DeclineBull Pennant - The Legal Advocate
H.C. Wainwright Maintains Tarsus Pharmaceuticals(TARS.US) With Buy Rating, Maintains Target Price $88 - Moomoo
Tarsus Pharmaceuticals Inc (TARS) 財務データ
収益
当期純利益
現金流量
EPS
0.74%
1.44%
大文字化:
|
ボリューム (24 時間):